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ABSTRACT
Background and purpose CADASIL (cerebral autosomal
dominant arteriopathy with subcortical infarcts and
leukoencephalopathy) is a rare genetic disease caused by
NOTCH3 gene mutations. A dysfunction in vasoreactivity
has been proposed as an early event in the pathogenesis
of the disease. The aim of this study was to verify whether
endothelium dependent and/or independent function is
altered in CADASIL patients with respect to controls.
Methods Vasoreactivity was studied by a non-invasive
pletismographic method in 49 mildly disabled CADASIL
patients (30e65 years, 58% male, Rankin scale #2) and
25 controls. Endothelium dependent vasodilatation was
assessed by reactive hyperaemia (flow mediated
dilationeperipheral arterial tone (FMD-PAT)) and
endothelium independent vasoreactivity by glyceryl
trinitrate (GTN) administration (GTN-PAT).
Results Patients and controls showed comparable age,
gender and cardiovascular risk factor distribution. GTN-PAT
values were significantly lower in CADASIL patients (1.54
(1.01 to 2.25)) than in controls (1.89 (1.61 to 2.59);
p¼0.041). FMD-PAT scores did not differ between
patients and controls (1.88 (1.57 to 2.43) vs 2.08 (1.81 to
2.58); p¼0.126) but 17 CADASIL patients (35%) had FMD-
PAT scores below the fifth percentile of controls. FMD-PAT
and GTN-PAT values correlated both in controls (r¼0.648,
p<0.001) and CADASIL patients (r¼0.563, p<0.001). By
multivariable logistic regression for clinical and laboratory
variables, only GTN-PAT (OR 0.39, 95% CI 0.15 to 0.97;
p¼0.044) was independently associated with FMD-PAT
below the fifth percentile in CADASIL patients.
Conclusions The impaired vasoreactivity observed in
CADASIL patients highlights the fact that both endothelial
and smooth muscle functional alterations may already be
present in mildly disabled subjects. The improvement in
vascular function could be a new target for
pharmacological trials in CADASIL patients.
INTRODUCTION
CADASIL (cerebral autosomal dominant arterio-
pathy with subcortical infarcts and leukoence-
phalopathy) is a rare genetic disease caused by
mutations in the NOTCH3 gene on the short arm
of chromosome 19. The NOTCH3 gene encodes
a cytoplasmic membrane receptor involved in
cellular differentiation and cell cycle regulation in
neuronal and vascular development during
embryogenesis.1 This receptor protein is predomi-
nantly and constitutively expressed in vascular
smooth muscle cells (VSMCs) in adult subjects
where its role remains to be defined.
Clinical manifestations of CADASIL are migraine
with aura, recurrent strokes starting in mid-adult-
hood and psychiatric disturbances. CADASIL may
progress to severe motor disability with pseudo-
bulbar palsy and dementia of the subcortical type.2 3
This non-atherosclerotic and non-amyloid angiop-
athy specifically affects capillaries and small sized
arteries of the brain but also other organs,4 indi-
cating that CADASIL is a systemic vascular disease.
Morphological alterations include loss of normal
VSMC anchorage to the extracellular matrix and
other nearby cells, abnormalities of the cytoskel-
eton and endothelium,1 thickened arterial wall
with ensuing lumen stenosis,5 granular osmiophilic
material deposits within the media and adventitia,6
and progressive degeneration and loss of VSMCs.
In addition, muscle and skin biopsies of
CADASIL patients exhibited endothelial structural
changes7 that may interfere with endothelial nitric
oxide synthase activity and nitric oxide bioavail-
ability and cause endothelial dysfunction (ED). ED,
found in many cardiovascular (CV) diseases, is
a strong predictor of CV adverse events.8 9
In CADASIL patients, impaired vasoreactivity
has been previously suggested as a functional
consequence of vascular wall modifications.
Decreased cerebral basal perfusion and haemody-
namic reserve in response to acetazolamide10 or
carbon dioxide11 have been reported. Human small
arteries studied ex vivo displayed abnormal reac-
tivity to vasoconstricting agents and normal
response to vasodilatory substances.12 CADASIL
patients presented with impaired endothelial
dependent function in forearm resistance arteries
with respect to healthy non-smoking controls.13
On the other hand, endothelium independent
vasodilation, an index of VSMC function, has been
poorly investigated.13 14
Measurement of peripheral vasodilator response
using a fingertip pulse amplitude tonometry device
was recently validated15 and has been recognised as
a valid tool to identify patients with early stage
coronary artery disease.16
The aim of our study was to verify whether
endothelium dependent and independent function,
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assessed by fingertip pulse amplitude tonometry, is altered in
CADASIL patients with respect to controls of comparable age,
gender and CV risk factors.
METHODS
Study population
We studied 49 subjects, aged 30e65 years, with a diagnosis of
CADASIL confirmed by the identification of a mutation in the
NOTCH3 gene, in combination with typical neuroimaging
abnormalities.17 We enrolled both patients with overt clinical
disease and relatives of patients with established CADASIL who
had requested presymptomatic genetic testing. None of the
patients had experienced a cerebrovascular accident, myocardial
infarction or pulmonary embolism in the 3 months preceding the
study. None had evidence of autoimmune disorders, or liver or
renal disease. We chose to study only mildly disabled (Rankin Scale
score #2) subjects and excluded patients with Rankin Scale scores
>2 or demented individuals (DSM-IV criteria, with a SIDAM
score <33) to ensure informed consent and adequate cooperation.
At enrolment, a complete clinical history was collected,
including period of symptom onset, concomitant treatments
and CV risk factors, such as hypertension,18 hyper-
cholesterolaemia,19 diabetes,20 moderate intermediate hyper-
homocysteinaemia (plasma total homocysteine $15 and
<100 mmol/l)21 and smoking habit. A complete neurological
examination was performed in all patients. Disability was
assessed by the Rankin Scale.
Between January and March 2010, 25 subjects of similar age
and sex, with no history, signs or symptoms of cerebrovascular
and/or CV disease, who had been referred to our institution for
vasoreactivity studies to improve the definition of their cardio-
vascular risk profile, were enrolled as controls.
The study was approved by the institutional review boards of
the participating units. All patients gave written informed
consent to participate.
Biochemical measurements
After an overnight fast, an antecubital vein was cannulated and
blood was drawn into different prechilled Vacutainer tubes for
biochemical determinations. Routine biochemistry was
performed by standard laboratory methods. The concentration
of plasma total homocysteine was evaluated, according to
a method validated in our laboratory,22 by high performance
liquid chromatography after a reducing step with tri-n-butyl-
phosphine, followed by sample derivatisation with ammonium-
7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate, a specific reagent
for the sulfhydryl group.
Peripheral vasoreactivity
Endothelium dependent and independent vasodilation was
assessed by a non-invasive pletismographic method (Endo-
PAT2000, Itamar Medical Ltd, Caesarea, Israel) based on the
registration of pulsatile blood volume in the fingertips of both
hands. The Endo-peripheral arterial tone (PAT) equipment
consists of two finger mounted probes, composed of inflatable
latex air cushions within a rigid external case; pulsatile volume
changes of the fingertip are sensed by a pressure transducer,
located at the end of each probe, and transferred to a personal
computer where the signal is band pass filtered (0.3e30 Hz),
amplified, displayed and stored.
Endo-PAT studies were performed with the patient in the
supine position and both hands on the same level in a comfort-
able, thermoneutral environment. Systolic and diastolic blood
pressures and heart rate were measured before starting the test.
A blood pressure cuff was placed on one upper arm (study arm)
while the contralateral served as a control (control arm). After
a 10 min equilibration period, signal recording started. The blood
pressure cuff on the study arm was inflated to 60 mm Hg above
systolic pressure for 5 min. The cuff was then deflated to induce
reactive hyperaemia where the signal was recorded for 10 min.
After signal recovery to baseline, we assessed the endothelium
independent response. Provided that pretest blood pressure was
$110/70 mm Hg, patients were given two sublingual puffs
(300 mg) of glyceryl trinitrate (GTN). Volume changes at the
fingertips were then recorded for 10 min.
The PATscore output, an index of endothelial dependent flow
mediated dilation (FMD), was automatically calculated as the
ratio of the amplitude of the PAT signal averaged post and pre
occlusion (FMD-PAT).
Endothelium independent vasodilatation, evoked by GTN,
was manually assessed as the mean ratio of PATsignal in control
and study arms post and pre drug administration (GTN-PAT) by
two independent observers; reading results were then averaged.
Intraobserver and interobserver variability of GTN-PAT readings
in our laboratory are 1.7% and 1.5%, respectively.
Brain magnetic resonance
MR imaging scans were performed for the diagnosis of white
matter lesions and cerebral infarctions on 1.5 T scanners. T1
weighted images and fluid attenuated inversion recovery
(FLAIR) weighted images were obtained in the axial plane. MR
images were examined to differentiate between white matter
lesions, characterised by isointense signals on T1 weighted
images and hyperintense signals on T2 weighted and FLAIR
images, and cerebral infarction, characterised by hypointense
signals on T1 weighted images and hyperintense signals on T2
weighted and FLAIR images.
In a subgroup of 33 subjects, white matter lesions were clas-
sified by one independent observer as periventricular hyper-
intensities (PVH), which adjoined the lateral ventricle, and deep
white matter hyperintensities (DWMH), located in the deep
white matter, apart from the lateral ventricle. PVH and DWMH
scores were evaluated according to the scale of Fazekas23: score
of PVH¼0 (absence), 1 (caps or pencil thin lining), 2 (smooth
halo) or 3 (irregular PVH extending into the deep white matter);
score of DWMH¼0 (absence), 1 (punctuate foci), 2 (beginning
confluence of foci) or 3 (large confluent areas).
Statistical analysis
Data are presented as median and IQR (IeIII) or frequency (%).
Between group differences were tested by the Student’s t test for
continuous variables, and the c2 test or Fisher ’s exact test for
categorical variables. The ManneWhitney and KruskalleWallis
tests were used for skewed variables. Correlations were calcu-
lated using the Spearman rank correlation test. Non-parametric
Spearman’s rank correlation coefficients are displayed as ‘r’. The
z statistic was used to compare the correlation coefficients for
FMD-PAT and GTN-PAT in controls and CADASIL patients.
The association between altered FMD-PAT (below the fifth
percentile of the control population) in CADASIL patients and
clinical or laboratory parameters was assessed by univariate
logistic regression; significant variables (p<0.10) were then
entered into a multivariate logistic regression model to identify
those independently associated with altered FMD-PAT.
Statistical analysis was carried out with the Statistical
Package for the Social Sciences (SPSS Inc) release V.17.0 for
Windows. The level of significance was set at p#0.05.
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RESULTS
CADASIL population
Among the 49 enrolled subjects, 34 (74%) had overt clinical
disease: 22 (45%) had suffered a previous cerebrovascular event,
transient ischaemic attack (n¼11) or stroke (n¼11); eight (16%)
subjects had a history of migraine without other manifestation
while four (8%) presented with psychiatric symptoms. The
median period since onset of symptoms was 8 (3e13) years.
Fifteen subjects (31%) were asymptomatic mutation carriers.
NOTCH3 gene mutations were all missense, involving a Cys
residue, and were distributed between exon 2 and exon 22
(figure 1), with the greatest frequency in exon 4. Overall, 29
subjects had mutations in exons 2e4 and 12 in exons 19e22.
Most patients had diffuse and severe white matter hyper-
intensities on MR scans, as classified by the Fazekas scale (table 1).
Both PVH (grade 3, 55% vs 64%, p¼0.268) and DWMH (grade 3,
46% vs 64%, p¼0.166) distribution overlapped between asymp-
tomatic and symptomatic patients.
Comparison between CADASIL patients and controls
Clinical and biochemical characteristics of the study groups are
presented in table 2. CADASIL patients and controls had
a similar age and gender distribution and prevalence of CV risk
factors. Controls had significantly higher glucose and total
cholesterol levels than patients but similar low density lipo-
protein cholesterol concentrations. Antihypertensive therapy
was balanced between groups, while a higher proportion of
CADASIL subjects were on statins.
Systolic blood pressure levels before the vasoreactivity study
were slightly, but significantly, lower in CADASIL patients than
in controls. After GTN, systolic blood pressure decreased
significantly more in controls (10 (19; 10) mm Hg) than in
CADASIL patients (5 (10; 0) mm Hg; p<0.001).
CADASIL patients showed a significantly lower vasodilatory
response to GTN than controls (1.54 (1.01e2.25) vs 1.89
(1.61e2.59); p¼0.041). Conversely, median FMD-PAT values did
not differ between groups (1.88 (1.57e2.43) vs 2.08 (1.81e2.58);
p¼0.126); however, 17 CADASIL patients (35%) had values
below the fifth percentile of the FMD-PAT score control distri-
bution (figure 2); the finding did not appear to be influenced by
statin administration.
FMD-PATandGTN-PATvalues correlated significantly (figure 3)
both in controls (r¼0.648, p<0.001) and CADASIL patients
(r¼0.563, p<0.001).
Predictors of abnormal vasoreactivity in CADASIL patients
Duration of symptoms did not correlate either with FMD-PAT
(r¼0.029) or with GTN-PAT (r¼0.058). Vasoreactivity did not
differ between the two largest groups of patients classified
according to the mutation site (exons 2e4, n¼29 vs exons
19e22, n¼12): FMD-PAT and GTN-PAT were 1.80 (1.68e2.43)
and 1.56 (1.03e2.20) in the former vs 1.95 (1.46e2.49) and 1.35
(0.98e2.02) in the latter group (p¼0.641 and p¼0.403, respec-
tively). Furthermore, vasoreactivity parameters were not influ-
enced by white matter changes expressed by PVH and DWMH
scores, as depicted in figure 4 (NS for all comparisons).
We tested by univariate logistic regression clinical, functional
and laboratory candidate predictors of abnormal endothelium
dependent vasodilation (table 3). Significant variables (p<0.10)
were then entered into a multivariate logistic regression model:
only lower GTN-PAT values were independently associated with
abnormal FMD-PAT (OR 0.39, 95% CI 0.15 to 0.97; p¼0.044).
At the 1 year follow-up, no impact of altered vasoreactivity on
phenotypic manifestations of the disease was apparent. Overall
disease progression in terms of disability was modest: the
Rankin Scale progressed only in the four patients who had grade
2 at baseline to grade 3 (p¼0.180). One patient developed
a cerebrovascular event with documented ischaemic lesions on
brain MR imaging 12 days after the ENDOPAT study where his
FMD-PATwas 2.48.
DISCUSSION
We investigated endothelium dependent and independent vaso-
reactivity in a large series of CADASIL patients who were
compared with healthy controls stratified by the presence of CV
risk factors. To our knowledge, this is the first time such
a comparison has been conducted. The main finding of the
present study was that endothelium independent vasoreactivity
was significantly altered in patients with respect to controls,
a finding that supports the pathophysiological role of VSMC
dysfunction in CADASIL. Moreover, despite similar median
FMD-PATscores between patients and controls, one-third of our
CADASIL subjects at an early stage of clinical impairment
showed an altered endothelium dependent vasodilation, below
the fifth percentile of normal.
The rationale for the study of both endothelium dependent
and independent vasodilation in CADASIL rests on the molec-
ular mechanisms of the disease whereby the NOTCH3 geneFigure 1 Distribution of NOTCH3 mutations in the study population.
Table 1 Distribution of periventricular hyperintensity and deep
white matter hyperintensity scores in a subgroup of CADASIL
patients
No (%)
PVH score (n¼33)
#1 7 (21)
2 6 (18)
3 20 (61)
DWMH score (n¼33)
#1 4 (12)
2 10 (30)
3 19 (58)
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy; DWMH, deep white matter hyperintensities; PVH, periventricular
hyperintenties.
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encoded receptor is constitutively expressed in VSMC, and
morphological abnormalities in these patients are observed both
in vascular smooth muscle and endothelial cells.
Nitric oxide, generated from the oxidation of L-arginine by
endothelial nitric oxide synthase, is a key molecular mediator of
normal endothelial function. The reduction in nitric oxide
bioactivity, through an increase in vascular reactive oxygen
species, contributes to impaired vascular relaxation, platelet
aggregation and enhanced leucocyte adhesion to the endothe-
lium.24 ED is the earliest phenotypic change in the vasculature
following exposure to atherothrombotic risk factors: hyperten-
sion, hypercholesterolaemia, smoking, diabetes and hyper-
homocysteinaemia induce ED in the absence of established
atherothrombotic disease.
Peripheral ED is associated with an increased risk of cardiac
and cerebrovascular events.9 25 Transient ischaemic attacks and
ischaemic strokes are the most frequent manifestations of
CADASIL and occur in 60e85% of patients.2 26 ED may there-
fore have a crucial role in the pathogenesis and progression of
disease.
Several pieces of indirect evidence of ED involvement in
CADASIL are available. Intravenous infusion of L-arginine, the
substrate for endothelial nitric oxide synthase, significantly
enhanced vasoreactivity in CADASIL patients compared with
controls.27 Compared with controls, CADASIL patients showed
higher plasma levels of asymmetric dimethylarginine, a biolog-
ical ED marker,28 and lower concentrations of endothelial
progenitor cells that participate in the maintenance of endo-
thelial structure and function.29
Stenborg et al13 observed a reduction in hyperaemic maximal
blood flow velocity in the brachial artery of CADASIL patients
compared with healthy, non-smoking controls without regular
medications.
Our CADASIL patients were similar in terms of risk factors
and history of vascular disease to other affected series that
Table 2 Clinical characteristics of the study subjects
Controls (n[25) CADASIL (n[49) p Value
Age (years) 46 (38e51) 46 (40e51) 0.985*
Male gender 14 (56) 27 (55) 1.000
CV risk factors (any) 13 (52) 20 (41) 0.460
Smoking habit 5 (20) 13 (27) 0.582
Hypertension 7 (28) 8 (16) 0.359
Hypercholesterolaemia 5 (20) 8 (16) 0.752
Hyperhomocysteinaemia >15 mmol/l 1 (4) 2 (4) 1.000
Laboratory findings
Total cholesterol (mmol/l) 5.74 (5.17e6.38) 5.30 (4.42e5.76) 0.013*
LDL cholesterol (mmol/l) 3.51 (3.02e3.98) 3.39 (2.35e3.98) 0.145*
Triglycerides (mmol/l) 0.99 (0.69e1.56) 1.15 (0.69e1.70) 0.671y
Fasting glucose (mmol/l) 5.22 (4.61e5.44) 4.89 (4.33e5.28) 0.047*
Plasma homocysteine (mmol/l) 8.34 (7.53e9.69) 8.39 (7.13e10.40) 0.904y
Creatinine clearance (ml/min) 116 (92e131) 111 (96e132) 0.900y
Folate (nmol/l) 12.5 (10.1e21.0) 15.2 (10.8e23.7) 0.314y
Vitamin B12 (pmol/l) 321 (259e399) 308 (225e384) 0.741*
Drug therapy
RAS inhibitors 3 (12) 6 (12) 1.000
b-blockers 2 (8) 2 (4) 0.600
Statins 1 (4) 7 (14) 0.253
Vital signs at PAT study
Systolic blood pressure (mm Hg) 130 (128e140) 120 (110e125) <0.001y
Diastolic blood pressure (mm Hg) 85 (80e90) 80 (70e85) 0.012y
Heart rate (beats/min) 65 (60e71) 68 (62e76) 0.144*
Vasoreactivity
FMD-PAT 2.08 (1.81e2.58) 1.88 (1.57e2.43) 0.126y
GTN-PAT 1.89 (1.61e2.59) 1.54 (1.01e2.25) 0.041y
Data are presented as number (frequency %) or median (IQR).
p Values are by c2 or Fisher’s exact test and the *Student’s t test or yManneWhitney test.
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CV, cardiovascular; FMD, flow mediated dilation; GTN, glyceryl trinitrate; LDL, low
density lipoprotein; PAT, peripheral arterial tonometry; RAS, renineangiotensin system.
Figure 2 Distribution of flow mediated dilationeperipheral arterial tone
(FMD-PAT) in controls and cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy (CADASIL) patients.
Each subject is represented by an open circle; CADASIL patients on
statins are represented by filled circles.
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detailed prevalence and characteristics of variables related to
vascular function.30e32 To account for the detrimental effect of
CV risk factors on endothelial function, unlike previous studies,
we enrolled control subjects with a similar prevalence of CV risk
factors in comparison with CADASIL patients. This aspect
might explain why individual FMD-PAT scores did not differ
between groups.
Endothelium independent vasoreactivity has been poorly
investigated in CADASIL to date. GTN acts as an exogenous
nitric oxide donor directly on VSMCs, to induce endothelium
independent vasodilation. Consistent with a primary
involvement of VSMCs in CADASIL, our patients showed,
despite relative preservation of endothelial function, a signifi-
cantly lower GTN response than controls. Several lines of
evidence support the notion that the early and progressive loss
of VSMCs could result in premature vessel wall weakness,6 as
confirmed by ultrastructural studies.7 In agreement with this
pathophysiological substrate, we demonstrated VSMC func-
tional impairment, as expressed by altered endothelium inde-
pendent vasodilation, in the largest series so far reported and in
comparison with a control population balanced by major CV
risk factors. Gobron et al14 did not observe any difference
between 23 CADASIL patients and 23 matched controls
without CV risk factors, in terms of changes in brachial artery
diameter after sublingual GTN administration or in cutaneous
blood flow after the iontophoretic delivery of sodium nitro-
prusside. Stenborg et al13 found no significant differences in
forearm blood flow after infusion of sodium nitroprusside
between 10 CADASIL patients and 20 age and gender
matched, healthy, non-smoking control subjects. These unex-
pected findings were probably due to the relatively limited
cohort size and should be viewed with caution. In contrast,
alterations in endothelium independent vasoreactivity found
in our large CADASIL series are consistent with early struc-
tural changes in VSMCs and underscore the systemic nature of
the disease. Accordingly, a relevant feature of our study is
assessment of vasoreactivity at the level of the peripheral
vascular beds where the peculiar and ubiquitous involvement
of the microvasculature typical of CADASIL may better be
detected.33
Figure 3 Non-parametric correlation
between endothelium dependent and
independent vasodilation expressed by
flow mediated dilationeperipheral
arterial tone (FMD-PAT) and glyceryl
trinitrate (GTN)-PAT scores,
respectively, in controls (A) and
cerebral autosomal dominant
arteriopathy with subcortical infarcts
and leukoencephalopathy (CADASIL)
patients (B). Although the correlation
appears closer among controls, no
difference was found between the
coefficients of the two groups (z
statistic¼0.519, p¼0.603).
Figure 4 Relationship between white
matter hyperintensities and
endothelium dependent (flow mediated
dilationeperipheral arterial tone (FMD-
PAT), upper panels) and endothelium
independent (glyceryl trinitrate (GTN)-
PAT, lower panels) vasodilation.
Differences among severity grades
were not significant for all comparisons
(KruskalleWallis test). DWMH, deep
white matter hyperintensities; PVH,
periventricular hyperintensities.
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The loss of systemic arteriolar wall tone caused by VSMC
degeneration may lead to failure of cerebral autoregulation with
chronic hypoperfusion or abrupt lack of perfusion. The low
blood pressure values found in our CADASIL patients during day
measurements compared with controls are consistent with
previous reports.34 A functional failure of brain structures and
connections controlling circadian blood pressure variations,
secondary to white matter damage, may lead to hypotension
that was also found to correlate with global cognitive deterio-
ration. Decreasing or loss of cerebral vasoreactivity is considered
the pathophysiological basis for the haemodynamic changes
leading to subcortical chronic hypoperfusion and ischaemic
lacunar lesions.10 35
We found no correlation between specific mutations or
mutation site and vasoreactivity. The phenotypic variability of
CADASIL despite the highly stereotyped nature of Notch3
mutations is well known. The dominant manifestations may
vary in different families, and the clinical picture and functional
course may also differ among individuals of the same family.
Someone with the mutation may remain asymptomatic for long
periods, even with well defined lesions on MR imaging, while
others exhibit major symptoms, such as transient ischaemic
attacks or lacunar infarcts, migraine with aura, depression or
anxiety, or slow evolution of cognitive impairment. Potential
factors accounting for this variability include environmental
influences and additional genetic factors, such as specific func-
tional polymorphisms.36e38 In line with these previous findings,
the lack of correlation between mutation site and vasoreactivity
in our series is not surprising.
The white matter lesion load has been suggested to influence the
nature and severity of clinical manifestations. Conversely, the present
study confirms previous observations by our group,17 as even
asymptomatic subjects showed advanced white matter changes in
a proportion comparable with subjects with overt disease.
The influence of conventional cardiovascular risk factors on
disease progression was examined by Singhal et al32 who found
an association between smoking and an earlier age of onset for
stroke/transient ischaemic attack. However, these findings await
confirmation. To date, older age is the only firmly established
risk factor for disease progression in CADASIL, leaving a large
proportion of the phenotypic variance unexplained.
Clinical implications
Our findings may be of interest for the management of
CADASIL patients in clinical practice. As our controls were
balanced by type and overall CV risk factor burden, the finding
of similar between group FMD-PAT scores points to the
importance of intensive risk factor treatment in CADASIL. All
patients should stop smoking, and blood pressure and low
density lipoprotein cholesterol levels close to those recom-
mended for secondary prevention should be targeted, even in
subjects with no clinical manifestations of the disease.
The prognostic value of altered endothelium independent
vasoreactivity in CADASIL patients is as yet unclear and needs
to be determined in longitudinal studies. Drugs directed towards
improving vasoreactivity and preserving the endothelium, by
ameliorating global vascular function, might positively impact
on outcome. Novel therapeutic options targeted to improve
endothelial and VSMCs function need to be assessed in ad hoc
clinical trials.
Some limitations of our study deserve consideration. This is
a cross sectional investigation and no inferences can be made on
the prognostic role of observed abnormalities in CADASIL
patients. The 1 year follow-up findings did not seem to suggest
an impact of altered vasoreactivity on short term disease
progression Although we observed an imbalance in drug treat-
ment between cases and controls, no net impact of statins on
vasoreactivity was found.
CONCLUSION
The impaired vasoreactivity observed in our CADASIL patients
highlights the fact that both endothelial and smooth muscle
functional alterations may already be present in mildly disabled
subjects. The detrimental impact of reduced endothelium
dependent and independent vasodilation in the evolution of
CADASIL should be ascertained in large prospective cohort
studies. Improvement of vascular function by increasing nitric
oxide bioavailability could be a new target for pharmacological
trials in the CADASIL population.
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Table 3 Univariate predictors of abnormal flow mediated
dilationeperipheral arterial tone in CADASIL patients
p Value OR (95% CI)
Age (per year) 0.128 1.07 (0.98 to 1.16)
Male vs female gender 0.825 0.88 (0.27 to 2.85)
Presence vs absence of clinical symptoms 0.160 2.80 (0.66 to 3.60)
Onset of clinical symptoms (years) 0.816 1.01 (0.94 to 1.09)
Previous cerebrovascular event vs no
event
0.703 0.79 (0.24 to 2.61)
Rankin scale (0 vs >0) 0.300 1.91 (0.56 to 6.48)
PVH score (n¼33)
#1 (reference) 0.323 1 (e)
2 0.396 0.37 (0.39 to 3.60)
3 0.133 0.25 (0.04 to 1.52)
DWMH score (n¼33)
#1 (reference) 0.579 1 (e)
2 0.733 0.66 (0.06 to 6.87)
3 0.361 0.36 (0.04 to 3.25)
Cardiovascular risk factors
Smoking habit (yes vs no) 0.740 1.25 (0.34 to 4.66)
Hypertension (yes vs no) 0.084 4.03 (0.83 to 19.59)
Hypercholesterolaemia (yes vs no) 0.327 2.15 (0.46 to 9.99)
Hyperhomocysteinaemia >15 mmol/l
(yes vs no)
0.648 1.94 (0.11 to 33.05)
Laboratory findings
Total cholesterol (per mmol/l) 0.506 1.01 (0.99 to 1.02)
LDL cholesterol (per mmol/l) 0.260 1.01 (0.99 to 1.03)
Triglycerides (per mmol/l) 0.576 1.00 (0.99 to 1.01)
Fasting glucose (per mmol/l) 0.097 1.06 (0.99 to 1.12)
Plasma homocysteine (per mmol/l) 0.285 1.13 (0.90 to 1.41)
Creatinine clearance (per ml/min) 0.212 1.01 (0.99 to 1.03)
Folate (per nmol/l) 0.382 1.01 (0.99 to 1.02)
Vitamin B12 (per pmol/l) 0.805 1.00 (1.00 to 1.01)
Drug therapy
RAS inhibitors (yes vs no) 0.407 2.07 (0.37 to 11.60)
b-blockers (yes vs no) 0.648 1.94 (0.11 to 33.05)
Statins (yes vs no) 0.626 1.50 (0.29 to 7.65)
Vital signs at PAT study
Systolic blood pressure (per mm Hg) 0.572 1.01 (0.97 to 1.06)
Diastolic blood pressure (per mm Hg) 0.323 1.05 (0.96 to 1.15)
Heart rate (per beats/mim) 0.767 0.99 (0.92 to 1.07)
GTN-PAT (per unit increment) 0.039 0.37 (0.14 to 0.95)
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy; DWMH, deep white matter hyperintensities; FMD, flow mediated
dilation; GTN, glyceryl trinitrate; LDL, low density lipoprotein; PAT, peripheral arterial
tonometry; PVH, periventricular hyperintenties; RAS, renineangiotensin system.
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APPENDIX
Study participants
CNR Clinical Physiology Institute, Milan: Raffaele Caruso, Marina Parolini, Valentina
Sedda, Anna Maria Tonini, Chiara Boroni, Stefania Zuddas. Institute of Translational
Pharmacology, CNR, Rome: Liana Veneziano. Department of Neurological Sciences
First and Second Medical School University of Rome La Sapienza, Rome: Ada Francia,
Francesco Orzi; Department of Neurological and Psychiatric Sciences, University of
Florence: Raffaella Valenti, Cristina Sarti. Neuroradiology Unit, Careggi University
Hospital, Florence, Italy: Marco Moretti, Stefano Chiti, Giampaolo Giordano. Depart-
ment of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milan: Claudio
Pelucchi.
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